PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6544635

Sinus node dysfunction.

C R Kerr·A O Grant·T L Wenger·H C Strauss
View original source ↗Export metadata ↓

Abstract

The syndrome of sinus node dysfunction has become increasingly recognized as a cause of symptoms and morbidity, particularly in the elderly population. This syndrome does not represent a homogeneous disease entity. Increased investigation has shown that many pathologic conditions and pathophysiologic mechanism may lead to one of the several clinical and electrocardiographic manifestations of the sick sinus syndrome. Attempts to improve diagnostic accuracy, identify underlying mechanisms and to predict the outcome of therapy have led to the development of various diagnostic tests. However, at present these have proven of limited clinical value and the mainstay of diagnosis remains ECG monitoring. Treatment is directed at the control of symptoms with pacemaker therapy for bradyarrhythmias and combined pacemaker and antiarrhythmic drug therapy for the bradycardiatachycardia syndrome.

Explore related subjects

Anti-Arrhythmia AgentsAutonomic Nervous SystemCarotid SinusElectrocardiographyHumansPrognosisSick Sinus SyndromeSinoatrial NodeJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C R Kerr, A O Grant, T L Wenger, H C Strauss. 1983. Sinus node dysfunction.. https://pubmed.ncbi.nlm.nih.gov/6544635/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Acute treatment of atrial fibrillation: why and when to maintain sinus rhythm.

Although not usually immediately life threatening, atrial fibrillation (AFib) poses a significant long-term risk to health. The best-documented and probably largest long-term risk in this condition is from thromboembolic complications, but this has been shown to be largely overcome by moderate intensity anticoagulation. In addition, however, AFib has significant detrimental effects on exercise capacity and overall quality of life, can cause or exacerbate heart failure, and imposes significant health-care burdens. Cardioversion, usually by transthoracic direct current shock, restores sinus rhythm in > 80% of patients, but recurrence of AFib over the weeks and months that follow decreases the value of this strategy. Antiarrhythmic drugs lessen the recurrence rate and add to the overall efficacy of achieving the treatment goal of restoring and maintaining sinus rhythm, rather than accepting permanent AFib with ventricular rate control and long-term thromboembolic prophylaxis. Whereas clear evidence exists that abolishing AFib makes patients feel better in the short-to-medium term, data on the economic viability or long-term efficacy of such a strategy are sparse. Management trials in AFib currently ongoing will provide some answers, but the decision as to whether restoring sinus rhythm is feasible and realistic in individual patients will remain a decision to be made on a case-by-case basis.

Anti-Arrhythmia Agents↗
PubMed1998

Acute treatment of atrial fibrillation.

Atrial fibrillation (AFib) is a common clinical entity, responsible for significant morbidity and mortality, but it also accounts for a large percentage of healthcare dollar expenditures. Efforts to treat this arrhythmia in the past have focused on subacute antithrombotic therapy and eventually use of antiarrhythmic drugs for maintenance of sinus rhythm. However, there has been a growing interest in the concept of acute electrical and pharmacologic conversion. This treatment strategy has a number of benefits, including immediate alleviation of patient symptoms, avoidance of antithrombotic therapy, and prevention of electrophysiologic remodeling, which is thought to contribute to the perpetuation of the arrhythmia. There is also increasing evidence that this is a cost-effective strategy in that it may obviate admission to the hospital and the cost of long-term therapy. This article represents a summary of the treatments that may be used acutely to control the ventricular response to AFib, prevent thromboembolic events, and provide for acute conversion either pharmacologically or electrically. It includes information on modalities that are currently available and those that are under active development. We anticipate that an active, acute treatment approach to AFib and atrial flutter will become the therapeutic norm in the next few years, especially as the benefits of these interventions are demonstrated in clinical trials.

Anti-Arrhythmia Agents↗
PubMed1998

Drug treatment of atrial fibrillation in the managed care era.

There are many reasons why one might wish to suppress atrial fibrillation (AFib) and attempt to maintain sinus rhythm. This article assumes that the clinical decision to maintain sinus rhythm has been made. That being the case, antiarrhythmic drug therapy is generally the first line of treatment of AFib. Currently in the United States, there are 8 available antiarrhythmic drugs that have demonstrated efficacy for preventing AFib. The drugs are quinidine, procainamide, disopyramide, flecainide, propafenone, moricizine, sotalol, and amiodarone. Because AFib tends to recur regardless of the drug selected, recurring in at least one-half of the patients being treated, no drug is clearly better than any other for suppression of AFib. Furthermore, because AFib is rarely life-threatening, occasional recurrence should be anticipated and should not be considered failure per se. The measure of drug efficacy is the frequency of recurrence. Before initiating drug therapy, the presence or absence of structural heart disease must be determined, because in the absence of structural heart disease, antiarrhythmic drugs generally can be given rather safely, but in the presence of structural heart disease, especially when associated with ventricular dysfunction, there is an important risk of developing ventricular proarrhythmia. Considerations for specific drug selection are discussed and an algorithm for therapy is suggested.

Anti-Arrhythmia Agents↗